Cal-Maine Foods enters October with a week's worth of contradictory signals: short sellers have been rebuilding positions into a 14% monthly decline, yet the borrow market remains far too loose to suggest any squeeze pressure is building.
The clearest shift this week is in short interest. At 10.1% of the free float, the short position is meaningfully elevated for a packaged-foods name. More telling is the pace: shorts added roughly 8.7% in a single week, reversing a month of gradual covering that had trimmed the position by around 5% through most of September. The re-accumulation coincides almost exactly with the stock's sharpest leg lower, down 6.3% on the week to $68.55. That kind of alignment, sellers covering into a bounce and then rebuilding as prices fall again, reflects conviction rather than opportunism. The ORTEX short score backs this up, ticking to 65.5 from 62.7 a week ago and ranking in the bottom 8th percentile of all stocks on the short-score factor.
Options traders are moving in the same direction, but the borrow market is not. The put/call ratio has climbed to 0.70, more than two standard deviations above its 20-day average of 0.59, and the highest defensive reading the options market has registered for this stock in several months outside the August spike that briefly pushed PCR above 0.90. That argues for caution. The lending market, however, tells a different story: availability is running at 188% of short interest, meaning lenders still hold nearly twice as many shares as are currently out on loan. Borrowing costs remain negligible at 0.50%. There is no supply squeeze embedded in this short position, which limits one of the more common catalysts for rapid unwinds.
The Street has been revising down in an orderly but persistent fashion. BMO Capital trimmed its target to $75 from $83 on 24 September while keeping a Market Perform rating, and Stephens & Co. followed two days earlier with a cut to $80 from $90, also holding Equal-Weight. StoneX downgraded the stock outright to Hold in early September. None of these are upgrades. The consensus target of $72.50 sits roughly 6% above the current price, but the direction of revisions has been one-way lower since mid-2025, and the forward earnings picture explains why: the EPS momentum factor ranks in the 1st percentile of the universe, and the PE multiple has expanded sharply to nearly 49x over the past month as earnings estimates fall faster than the stock. EV/EBITDA has moved in the same direction, adding 2.8 turns in 30 days to reach 10.7x. The bear case is straightforward: egg prices have come off sharply from their highs, the conventional flock is down 13.6% year-on-year, and net sales have fallen 19.4% from peak levels. The bull case rests on management's plan to grow prepared-foods capacity by over 30% in the next 18 months and the fact that chick-hatch numbers are running more than 11% ahead of a year ago, suggesting the supply rebuild is real, even if prices have not cooperated.
One item on the register worth noting: the activist filing from Adolphus Baker, the company's former CEO and Board Chair, who holds a Schedule 13D position at approximately 3% of the class. That filing has been amended five times since February 2025, most recently in August 2025. As with all 13D/G disclosures, the stated stake reflects the position as last disclosed around the 5% threshold, and holders can fall below that level without a further filing. Baker's position in the institutional table has barely moved, suggesting the stake is stable rather than actively building. American Century crossed the 5% threshold for the first time as recently as August, adding over 500,000 shares in its last reported period, making it one of the more notable fresh buyers among the major holders.
The next scheduled earnings event is not until 5 January 2027, leaving the stock to trade on macro egg-price data and USDA flock reports for the rest of the quarter. With shorts rebuilding, options skewing defensively, and analysts in a persistent trim cycle, what matters most between now and that print is whether egg-price indices stabilise or continue to erode the earnings trajectory that the revised $7.57 EPS estimate is already baking in.
See the live data behind this article on ORTEX.
Open CALM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
